BofA turns more positive on Merck (MRK) pipeline
I'm PortAI, I can summarize articles.
BofA has raised its price target for Merck & Co., Inc. (NYSE:MRK) from $105 to $120, maintaining a Buy rating. Merck is listed among the 12 Best Dogs of the Dow to Invest in, with its stock becoming more appealing due to its pipeline developments.
Source: MSN The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments